Abeona Therapeutics (ABEO) Posts Earnings Results

Abeona Therapeutics (NASDAQ:ABEO) released its quarterly earnings results on Friday. The biopharmaceutical company reported ($0.19) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.05), Bloomberg Earnings reports. Abeona Therapeutics had a negative net margin of 2,946.58% and a negative return on equity of 27.69%. The company had revenue of $0.22 million during the quarter, compared to the consensus estimate of $0.24 million. The company’s revenue was down 16.0% on a year-over-year basis.

Shares of Abeona Therapeutics (NASDAQ:ABEO) opened at $15.35 on Friday. Abeona Therapeutics has a 52-week low of $4.55 and a 52-week high of $22.75. The company has a market capitalization of $718.00, a PE ratio of -23.26 and a beta of 1.30.

A number of research firms have commented on ABEO. ValuEngine upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. HC Wainwright reiterated a “buy” rating and issued a $30.00 price target on shares of Abeona Therapeutics in a research report on Thursday, February 1st. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “buy” rating and set a $18.00 price target on the stock in a research report on Wednesday, November 22nd. Maxim Group set a $35.00 target price on Abeona Therapeutics and gave the company a “buy” rating in a research report on Monday, November 20th. Finally, BidaskClub upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Three equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $27.11.

An institutional investor recently bought a new position in Abeona Therapeutics stock. State Street Corp bought a new stake in shares of Abeona Therapeutics Inc (NASDAQ:ABEO) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 296,946 shares of the biopharmaceutical company’s stock, valued at approximately $1,900,000. State Street Corp owned approximately 0.74% of Abeona Therapeutics at the end of the most recent reporting period. Institutional investors own 62.64% of the company’s stock.

WARNING: “Abeona Therapeutics (ABEO) Posts Earnings Results” was first reported by StockNewsTimes and is the sole property of of StockNewsTimes. If you are reading this report on another domain, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this report can be read at https://stocknewstimes.com/2018/03/18/abeona-therapeutics-abeo-posts-earnings-results.html.

Abeona Therapeutics Company Profile

Abeona Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB).

Earnings History for Abeona Therapeutics (NASDAQ:ABEO)

Receive News & Ratings for Abeona Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abeona Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply